Fig. 1: Participant flow diagram for the phase 2a LM11A-31 clinical trial. | Nature Medicine

Fig. 1: Participant flow diagram for the phase 2a LM11A-31 clinical trial.

From: p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial

Fig. 1

Examples of major protocol violations included failure to meet inclusion or exclusion criteria (data changed or violation was not detected before dosing), use of prohibited medication that began during the treatment period (Methods), incomplete treatment (<80% compliance over the treatment period), final visit outside prespecified acceptable visit window (182 ± 7 days after baseline visit) or early withdrawal. PK population, pharmacokinetic study population. *Discontinued due to randomization failure.

Back to article page